亚胺培南-雷巴他定和美罗培南-沃诺拉赞对产 SME 碳青霉烯酶耐药黏质沙雷氏菌的活性。
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
机构信息
College of Pharmacy, University of Illinois at Chicago, Rockford, Illinois, USA.
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
出版信息
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02255-19.
Abstract
The enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.
摘要
该酶（SME）是一种染色体编码的碳青霉烯酶，目前尚无明确的最佳治疗方法。通过肉汤微量稀释法，对 8 种 SME 产生菌进行了各种β-内酰胺/β-内酰胺酶抑制剂和对照药物的评估。随后对 4 个分离株进行了时间杀伤分析。所有分离株均对亚胺培南、亚胺培南-雷巴坦和美罗培南耐药，但对头孢他啶、头孢他啶-阿维巴坦和美罗培南-沃巴坦敏感。头孢他啶、亚胺培南-雷巴坦和美罗培南-沃巴坦对 3、0 和 4 个分离株分别具有杀菌作用。美罗培南-沃巴坦可能是治疗严重 SME 产生菌感染的一个潜在选择。
相似文献
1
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02255-19.
2
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Int J Antimicrob Agents. 2021 Nov;58(5):106439. doi: 10.1016/j.ijantimicag.2021.106439. Epub 2021 Sep 20.
3
Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
J Glob Antimicrob Resist. 2024 Sep;38:247-251. doi: 10.1016/j.jgar.2024.06.007. Epub 2024 Jun 25.
4
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
5
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 2023 Dec 1;78(12):2795-2800. doi: 10.1093/jac/dkad225.
6
Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
Microbiol Spectr. 2024 Jun 4;12(6):e0034424. doi: 10.1128/spectrum.00344-24. Epub 2024 Apr 30.
7
Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Int J Antimicrob Agents. 2024 Apr;63(4):107113. doi: 10.1016/j.ijantimicag.2024.107113. Epub 2024 Feb 12.
8
Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
Int J Antimicrob Agents. 2022 Oct;60(4):106660. doi: 10.1016/j.ijantimicag.2022.106660. Epub 2022 Aug 18.
9
Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant .
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02048-18. Print 2019 Mar.
10
Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in .
Antimicrob Agents Chemother. 2023 May 17;67(5):e0007823. doi: 10.1128/aac.00078-23. Epub 2023 Apr 11.
引用本文的文献
1
Improved Blue Carba test and Carba NP test for detection and classification of major Class A and B carbapenemases, including dual producers, among Gram-negative bacilli.
J Clin Microbiol. 2024 Jul 16;62(7):e0125523. doi: 10.1128/jcm.01255-23. Epub 2024 Jun 21.
2
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.
Antibiotics (Basel). 2023 Dec 5;12(12):1700. doi: 10.3390/antibiotics12121700.
3
Clonal dissemination of highly virulent strains producing KPC-2 in food-producing animals.
One Health. 2023 Jun 21;17:100591. doi: 10.1016/j.onehlt.2023.100591. eCollection 2023 Dec.
4
Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in .
Antimicrob Agents Chemother. 2023 May 17;67(5):e0007823. doi: 10.1128/aac.00078-23. Epub 2023 Apr 11.
5
Mutations responsible for the carbapenemase activity of SME-1.
RSC Adv. 2022 Aug 15;12(35):22826-22842. doi: 10.1039/d2ra02849b. eCollection 2022 Aug 10.
6
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0025622. doi: 10.1128/aac.00256-22. Epub 2022 Jun 21.
7
Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales.
Front Med (Lausanne). 2021 Jan 20;7:616490. doi: 10.3389/fmed.2020.616490. eCollection 2020.
8
A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.
Infect Drug Resist. 2020 Nov 25;13:4297-4308. doi: 10.2147/IDR.S224228. eCollection 2020.
9
New β-Lactam-β-Lactamase Inhibitor Combinations.
Clin Microbiol Rev. 2020 Nov 11;34(1). doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.
本文引用的文献
1
Biochemical Activity of Vaborbactam.
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01935-19.
2
Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01426-19. Epub 2019 Sep 30.
3
Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00564-19. Print 2019 Oct.
4
In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
J Antimicrob Chemother. 2019 May 1;74(5):1300-1305. doi: 10.1093/jac/dkz010.
5
Pangenome of Serratia marcescens strains from nosocomial and environmental origins reveals different populations and the links between them.
Sci Rep. 2019 Jan 10;9(1):46. doi: 10.1038/s41598-018-37118-0.
6
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00280-18. Print 2018 Sep.
7
Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy.
J Antimicrob Chemother. 2018 May 1;73(5):1256-1262. doi: 10.1093/jac/dky028.
8
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02228-17. Print 2018 Apr.
9
Serratia marcescens harboring SME-4 in Brazil: A silent threat.
Diagn Microbiol Infect Dis. 2017 Apr;87(4):357-358. doi: 10.1016/j.diagmicrobio.2017.01.008. Epub 2017 Jan 20.
10
Serratia marcescens producing SME carbapenemases: an emerging resistance problem in the UK?
J Antimicrob Chemother. 2017 May 1;72(5):1535-1537. doi: 10.1093/jac/dkw567.
Zotero 插件